AAAAAA

   
Results: 1-25 | 26-35 |
Results: 26-35/35
DIURNAL-VARIATIONS IN THE PLASMA-CONCENTRATIONS OF MEVALONIC ACID IN PATIENTS WITH ABETALIPOPROTEINEMIA
Authors: PAPPU AS ILLINGWORTH DR
Citation: As. Pappu et Dr. Illingworth, DIURNAL-VARIATIONS IN THE PLASMA-CONCENTRATIONS OF MEVALONIC ACID IN PATIENTS WITH ABETALIPOPROTEINEMIA, European journal of clinical investigation, 24(10), 1994, pp. 698-702
IMPACT OF INCREASING CALCIUM IN THE DIET ON NUTRIENT CONSUMPTION, PLASMA-LIPIDS, AND LIPOPROTEINS IN HUMANS
Authors: KARANJA N MORRIS CD RUFOLO P SNYDER G ILLINGWORTH DR MCCARRON DA
Citation: N. Karanja et al., IMPACT OF INCREASING CALCIUM IN THE DIET ON NUTRIENT CONSUMPTION, PLASMA-LIPIDS, AND LIPOPROTEINS IN HUMANS, The American journal of clinical nutrition, 59(4), 1994, pp. 900-907
INDICATIONS FOR LOW-DENSITY-LIPOPROTEIN APHERESIS
Authors: GORDON BR STEIN E JONES P ILLINGWORTH DR
Citation: Br. Gordon et al., INDICATIONS FOR LOW-DENSITY-LIPOPROTEIN APHERESIS, The American journal of cardiology, 74(11), 1994, pp. 1109-1112
THE POTENTIAL ROLE OF ANTIOXIDANTS IN THE PREVENTION OF ATHEROSCLEROSIS
Authors: ILLINGWORTH DR
Citation: Dr. Illingworth, THE POTENTIAL ROLE OF ANTIOXIDANTS IN THE PREVENTION OF ATHEROSCLEROSIS, Journal of nutritional science and vitaminology, 39, 1993, pp. 190000043-190000047
LIPOPROTEIN METABOLISM
Authors: ILLINGWORTH DR
Citation: Dr. Illingworth, LIPOPROTEIN METABOLISM, American journal of kidney diseases, 22(1), 1993, pp. 90-97
THE EFFECTS OF N-3 FATTY-ACIDS ON PLASMA-LIPIDS AND LIPOPROTEINS AND OTHER CARDIOVASCULAR RISK-FACTORS IN PATIENTS WITH HYPERLIPIDEMIA
Authors: SCHMIDT EB KRISTENSEN SD DECATERINA R ILLINGWORTH DR
Citation: Eb. Schmidt et al., THE EFFECTS OF N-3 FATTY-ACIDS ON PLASMA-LIPIDS AND LIPOPROTEINS AND OTHER CARDIOVASCULAR RISK-FACTORS IN PATIENTS WITH HYPERLIPIDEMIA, Atherosclerosis, 103(2), 1993, pp. 107-121
MOLECULAR-GENETICS OF CHOLESTEROL ESTER HYDROLASE DEFICIENCY
Authors: MASLEN CL ILLINGWORTH DR
Citation: Cl. Maslen et Dr. Illingworth, MOLECULAR-GENETICS OF CHOLESTEROL ESTER HYDROLASE DEFICIENCY, Circulation, 88(4), 1993, pp. 424-424
LOVASTATIN 5-YEAR SAFETY AND EFFICACY STUDY
Authors: DAVIGNON J XHIGNESSE M MAILLOUX H FROHLICH J HAYDEN ML VANETTA H MISHKEL MA MCQUEEN MJ TAN MH WOLFE B NIKKILA E TIKKANEN MJ OJALA JP HELVE E DUJOVNE CA HORNIMAN S GOLDBERG I GINSBERG H GOLDBERG R FARKAS R HUNNINGHAKE D BELL L HELGREN R KNOPP R MCGINNIS B KWITEROVICH P GOLDBERG A BLOOM A MILLER V LAROSA J STOY DB GASPARIS G SCHONFELD G GOLDBERG A ANDERSON C DILLINGHAM M STEINBERG D WITZTUM J KELLY N WEBB H STEIN EA LAMKIN GE LEES RS LEES AM STEIN SW BRENNAN D ILLINGWORTH DR BACON SR GOTTO AM JONES PH FARMER JA PAYTONROSS C FELDMAN EB KUSKE TT DAVIS LC SAMUEL P CHIN B SCHOENFELD BH MARKOWSKI L HAVEL RJ FROST PH TUN P STONE NJ OYER DL RICHARDS L STEIN EA LAZKARZEWSKI P STEINER P TOBERT JA SHAPIRO DR KEEGAN ME GUTWEIN TM PAPPAS F MACHOY B PRAT A GAGNON G DOTY T NYBERG R
Citation: J. Davignon et al., LOVASTATIN 5-YEAR SAFETY AND EFFICACY STUDY, Archives of internal medicine, 153(9), 1993, pp. 1079-1087
MOLECULAR-GENETICS OF CHOLESTEROL ESTER HYDROLASE DEFICIENCY
Authors: MASLEN CL ILLINGWORTH DR
Citation: Cl. Maslen et Dr. Illingworth, MOLECULAR-GENETICS OF CHOLESTEROL ESTER HYDROLASE DEFICIENCY, American journal of human genetics, 53(3), 1993, pp. 926-926
HOW EFFECTIVE IS DRUG-THERAPY IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
Authors: ILLINGWORTH DR
Citation: Dr. Illingworth, HOW EFFECTIVE IS DRUG-THERAPY IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, The American journal of cardiology, 72(10), 1993, pp. 40000054-40000058
Risultati: 1-25 | 26-35 |